How would you manage a patient with stable axial spondyloarthritis who develops newly active IgA nephropathy?
Is there a role for immunosuppressive medications such as TNF inhibitors in the management of IgA nephropathy in this setting?
Answer from: at Academic Institution
Although the data are sparse, in general, the principles of treatment of IgAN in the setting of spondyloarthritis is similar to primary IgAN.
BP targets <120/80
RAS inhibitors or sparsentan
SGLT2 inhibitors
If persistent proteinuria despite above, targeted-release budesonide or oral corticost...
Sign in or Register to read more
Answer from: at Academic Institution
Increased serum IgA levels and IgA nephropathy are known to be an extra-articular feature although uncommon within the spectrum of spondyloarthropathies, just like uveitis, apical lung fibrosis, cardiac conduction defects, aortitis, etc., especially with AS (ankylosing spondylitis). If IgA nephropat...